uploads///featured image

An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

By

Nov. 20 2020, Updated 2:36 p.m. ET

Valeant’s performance

In 1Q18, Valeant Pharmaceuticals’ (VRX) revenues witnessed an ~5.0% decline to reach $2.0 billion. However, Valeant Pharmaceuticals reported 2.0% organic growth in 1Q18 compared to 1Q17.

Valeant Pharmaceuticals had an operating loss and net loss of ~$2.3 billion and ~$2.7 billion, respectively, in 1Q18. To learn more about its 1Q18 financial data, please read How Valeant Pharmaceuticals Performed in 1Q18.

Article continues below advertisement

Valeant to change its name

Valeant Pharmaceuticals recently announced that it would change its name to Bausch Health Companies, which is expected to be effective in July. Valeant Pharmaceuticals noted that the company would launch a new website. It expects to trade on the New York Stock Exchange and Toronto Stock Exchange with a new symbol, BHC. Valeant Pharmaceuticals’ CEO, Joseph C. Papa, noted that Bausch Health Companies more accurately represents the full scope of the company.

Recent agreements

In February, Valeant Pharmaceuticals entered into an agreement with Kaken Pharmaceuticals for the development and commercialization of products containing KP-470, an investigational chemical entity for the topical treatment of psoriasis.

According to the agreement, Valeant Pharmaceuticals received an exclusive license from Kaken Pharmaceuticals for the development and commercialization of drugs with KP-470 in the US, Canada, and European markets.

Analysts’ ratings

Of the 19 analysts tracking Valeant Pharmaceuticals in May, ~26.0% of the analysts recommended some form of a “buy” rating. On May 12, Valeant Pharmaceuticals had a consensus 12-month target price of $19.58, which represents an ~6.1% decline over the next 12 months.

Of the 31 analysts tracking Teva Pharmaceuticals (TEVA) in May, ~23.0% of the analysts recommended some form of a “buy” rating. On May 12, Teva Pharmaceuticals had a consensus 12-month target price of $19.44, which represents an ~0.67% return on investment over the next 12 months.

Of the 23 analysts tracking Mylan (MYL) in May, ~70.0% of the analysts recommended some form of a “buy” rating. On May 12, Mylan had a consensus 12-month target price of $49.71, which represents an ~29.4% return on investment over the next 12 months.

Of the 20 analysts tracking Eli Lilly (LLY) in May, ~60.0% of the analysts recommended some form of a “buy” rating. On May 12, Eli Lilly had a consensus 12-month target price of $90.63, which represents an ~9.9% return on investment over the next 12 months.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.